University of Nice Sophia Antipolis; UMR CNRS 7284/U INSERM 1081; Nice, France.
Centre Scientifique de Monaco; Monaco.
Oncoimmunology. 2014 Apr 9;3:e28399. doi: 10.4161/onci.28399. eCollection 2014.
The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELRCXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.
抗血管内皮生长因子 (VEGF) 和 VEGF 受体的抗血管生成药物在治疗肾细胞癌 (RCC) 中的长期疗效一直缺乏。我们已经表明，ELRCXCL 细胞因子及其 (C-X-C) 趋化因子受体，即 CXCR1 和 CXCR2，刺激癌细胞增殖、肿瘤炎症和血管生成。因此，这个调节癌症生长的关键分子连接点代表了一个关键的治疗靶点。
Zotero 插件